$8.77
6.70%
NYSE, Jan 02, 10:16 pm CET
ISIN
US5019761049
Symbol
KYTX

Kyverna Therapeutics Stock price

$8.77
+2.21 33.69% 1M
+5.95 210.44% 6M
-0.63 6.70% YTD
+4.85 123.72% 1Y
-13.23 60.14% 3Y
-13.23 60.14% 5Y
-13.23 60.14% 10Y
-13.23 60.14% 20Y
NYSE, Closing price Fri, Jan 02 2026
-0.63 6.70%
ISIN
US5019761049
Symbol
KYTX
Industry

Key metrics

Basic
Market capitalization
$501.0m
Enterprise Value
$330.1m
Net debt
positive
Cash
$171.1m
Shares outstanding
43.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
87.5%
Return on Equity
-47.6%
ROCE
-111.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-169.6m | $-173.5m
EBIT
$-171.6m | $-178.9m
Net Income
$-161.0m | $-167.4m
Free Cash Flow
$-158.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-41.2% | -23.1%
EBIT
-40.5% | -25.1%
Net Income
-44.8% | -31.8%
Free Cash Flow
-62.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.7
FCF per Share
$-3.6
Short interest
12.5%
Employees
129
Rev per Employee
$0.0
Show more

Is Kyverna Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Kyverna Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Kyverna Therapeutics forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Kyverna Therapeutics forecast:

Buy
92%
Hold
8%

Financial data from Kyverna Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
28% 28%
-
- Research and Development Expense 137 137
43% 43%
-
-170 -170
41% 41%
-
- Depreciation and Amortization 1.99 1.99
2% 2%
-
EBIT (Operating Income) EBIT -172 -172
40% 40%
-
Net Profit -161 -161
45% 45%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kyverna Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kyverna Therapeutics Stock News

Positive
Seeking Alpha
17 days ago
Kyverna Therapeutics is upgraded to 'Buy' based on strengthened financials and the potential for commercial launch by the end of 2026. Phase 2 data for mivocabtagene autoleucel shows strong efficacy and favorable safety in autoimmune indications, supporting late-stage advancement. A recent $100 million public offering and an untapped $125 million loan facility extend KYTX's cash runway into 202...
Neutral
Seeking Alpha
18 days ago
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
Neutral
GlobeNewsWire
18 days ago
EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of $7.50 per share.
More Kyverna Therapeutics News

Company Profile

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Head office United States
CEO Warner Biddle
Employees 129
Founded 2018
Website kyvernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today